Kynam Capital Management disclosed in a recent SEC filing that it sold 1,720,949 shares of Cogent Biosciences (NASDAQ: COGT), amounting to approximately $48.38 million. This reduction, which occurred in the fourth quarter, left Cogent as Kynam’s largest position, representing 13.99% of its reported assets under management (AUM). Despite the sale, Cogent’s stock has surged 360% over the past year, significantly outperforming the S&P 500’s 15% gain during the same period.
The sale reflects a strategic move to balance risk while maintaining a strong conviction in Cogent’s potential. The company’s lead candidate, bezuclastinib, recently received FDA acceptance, with a target action date set for December 30, 2026. Cogent’s robust cash position of $900.8 million ensures operational stability through 2028, supporting continued investment in its innovative pipeline targeting rare cancers.
Investors should note that Kynam’s decision to trim its position may indicate a disciplined approach to portfolio management rather than a lack of confidence in Cogent’s growth trajectory.
Source: fool.com